In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed drug manufacturers to reduce the maximum retail price (MRP) of three crucial cancer drugs. This directive follows the government's decision to exempt Trastuzumab Deruxtecan, Osimertinib, and Durvalumab from Customs duty and reduce GST rates on these medications.
